vla2001
VaccineexperimentalCOVID-19
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
5
Phase 4
0
Earliest trial started Dec 16, 2020 (NCT04671017)
Timeline
Indications
Studied for
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05545683 | Phase 3 | Dec 1, 2022 | Centro de Estudios en Infectogía Pediatrica |
| NCT05298644 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2022 | Valneva |
| NCT05364242 | Phase 2/Phase 3 (Phase 3) | May 9, 2022 | Valneva |
| NCT04956224 | Phase 3 | Aug 9, 2021 | Valneva |
| NCT04864561 | Phase 3 | Apr 26, 2021 | Valneva |
| NCT04671017 | Phase 1/Phase 2 (Phase 2) | Dec 16, 2020 | National Institute for Health Research, United Kingdom, Valneva |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Valneva | For profit | 5 | 5 | 2 | 2020 |
| Centro de Estudios en Infectogía Pediatrica | Academic/Hospital | 1 | 1 | 1 | 2022 |
| National Institute for Health Research, United Kingdom | Government | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1